256 related articles for article (PubMed ID: 12042886)
21. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
[TBL] [Abstract][Full Text] [Related]
22. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure.
Sanaka T; Funaki T; Tanaka T; Hoshi S; Niwayama J; Taitoh T; Nishimura H; Higuchi C
Nephron; 2002 May; 91(1):64-73. PubMed ID: 12021521
[TBL] [Abstract][Full Text] [Related]
23. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients.
Stein G; Franke S; Mahiout A; Schneider S; Sperschneider H; Borst S; Vienken J
Nephrol Dial Transplant; 2001 May; 16(5):999-1008. PubMed ID: 11328907
[TBL] [Abstract][Full Text] [Related]
24. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
Busch M; Franke S; Stein G; Wolf G;
Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
[TBL] [Abstract][Full Text] [Related]
25. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
26. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress".
Jadoul M; Ueda Y; Yasuda Y; Saito A; Robert A; Ishida N; Kurokawa K; Van Ypersele De Strihou C; Miyata T
Kidney Int; 1999 Jun; 55(6):2487-92. PubMed ID: 10354298
[TBL] [Abstract][Full Text] [Related]
27. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy.
Raj DS; Lim G; Levi M; Qualls C; Jain SK
Am J Kidney Dis; 2004 Jan; 43(1):154-60. PubMed ID: 14712439
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients.
Nur E; Brandjes DP; Schnog JJ; Otten HM; Fijnvandraat K; Schalkwijk CG; Biemond BJ;
Br J Haematol; 2010 Oct; 151(1):62-9. PubMed ID: 20678158
[TBL] [Abstract][Full Text] [Related]
29. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.
Yoshida N; Okumura K; Aso Y
Metabolism; 2005 Mar; 54(3):345-50. PubMed ID: 15736112
[TBL] [Abstract][Full Text] [Related]
30. Daily haemodialysis improves indices of protein glycation.
Floridi A; Antolini F; Galli F; Fagugli RM; Floridi E; Buoncristiani U
Nephrol Dial Transplant; 2002 May; 17(5):871-8. PubMed ID: 11981076
[TBL] [Abstract][Full Text] [Related]
31. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes.
Miura J; Yamamoto Y; Osawa M; Watanabe T; Yonekura H; Uchigata Y; Yamamoto H; Iwamoto Y
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):253-4. PubMed ID: 17185626
[No Abstract] [Full Text] [Related]
32. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
Klemm A; Franke C; Busch M; Müller A; Franke S; Lang D; Passlick-Deetjen J; Stein G
Clin Nephrol; 2004 Mar; 61(3):191-7. PubMed ID: 15077870
[TBL] [Abstract][Full Text] [Related]
33. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
[TBL] [Abstract][Full Text] [Related]
34. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
[TBL] [Abstract][Full Text] [Related]
35. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females.
Yoshikawa T; Miyazaki A; Fujimoto S
Med Sci Monit; 2009 Jun; 15(6):PH65-73. PubMed ID: 19478714
[TBL] [Abstract][Full Text] [Related]
36. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283
[TBL] [Abstract][Full Text] [Related]
37. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
38. Cardiac troponin T and advanced glycation end-products in hemodialysis patients.
Taki K; Tsuruta Y; Niwa T
Am J Nephrol; 2008; 28(5):701-6. PubMed ID: 18431051
[TBL] [Abstract][Full Text] [Related]
39. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.
Hricik DE; Wu YC; Schulak A; Friedlander MA
Clin Transplant; 1996 Dec; 10(6 Pt 1):568-73. PubMed ID: 8996781
[TBL] [Abstract][Full Text] [Related]
40. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
